
Please try another search
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Alex Choi | - | 2022 | Member of Scientific Advisory Board |
Vimal Kumar Kavuru | 56 | 2021 | Independent Chairman |
Sherry H-Y Chou | - | 2023 | Member of Scientific Advisory Board |
W. Taylor Kimberly | - | 2023 | Member of Scientific Advisory Board |
S. George Kottayil | 62 | 2021 | Director |
Edward Alan Neugeboren | 56 | 2023 | Independent Director |
Alejandro A. Rabinstein | - | 2023 | Member of Scientific Advisory Board |
R. Loch MacDonald | 63 | 2022 | Member of Scientific Advisory Board & Chief Medical Officer |
Prashant Kohli | 53 | 2021 | CEO & Director |
Andrew Ducruet | - | 2022 | Member of Scientific Advisory Board |
A. Brian Davis | 58 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review